Amedisys Reports Fourth Quarter and Year End 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up as AI enthusiasm eases worries over higher oil prices, yields
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil slides as US-Iran truce hopes outweigh Houthi attacks on Saudi Arabia
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Amedisys (AMED) Misses Q4 EPS by 10c, Beats on Revenue
February 26, 2025 4:32 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.96, $0.10 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $598.1 million versus the consensus estimate of $596.76 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
... More